Development of immunotherapeutic strategies for the treatment of malignant neoplasms

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Focused preclinical studies have been used to gain insight into the mechanism of therapeutic activity of cytokines, growth factors and biological response modifiers (BRMs). These data can then be used to develop a clinical hypothesis to facilitate the development of these new biological drugs. In this manuscript, we discuss a number of preclinical and clinical studies using interferon-γ, IL-2, and the colony stimulating factors. The importance of the systematic profiling of the biological activity of such biological drugs is emphasized and we discuss the utility of the mechanistic data in their clinical development. The overall preclinical approach identifies the cellular, biochemical or gene regulatory event that is associated with the therapeutic activity of a biologic and this surrogate (be it biological, chemical, or quality of life) is then used to optimize the clinical protocol in a phase lb trial. This, in theory, results in the rapid identification of the optimal dose, schedule and route of administration for subsequent testing in a phase II/III clinical trial.

Original languageEnglish (US)
Pages (from-to)215-236
Number of pages22
JournalBiotherapy
Volume4
Issue number3
DOIs
StatePublished - Mar 1 1992

Fingerprint

Colony-Stimulating Factors
Phase III Clinical Trials
Phase II Clinical Trials
Immunologic Factors
Regulator Genes
Clinical Protocols
Pharmaceutical Preparations
Interferons
Interleukin-2
Neoplasms
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Quality of Life
Cytokines
Therapeutics
Clinical Studies

Keywords

  • Biological Response Modifiers (BRMs)
  • colony stimulating factor granulocyte-macrophage (CSF-GM)
  • colony stimulating factor-granulocyte (CSF-G)
  • immunotherapy and immunopharmacology
  • interferon (IFN)
  • interferon-γ (IFN-γ)
  • interleukin-2 (IL-2)
  • metastasis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Development of immunotherapeutic strategies for the treatment of malignant neoplasms. / Talmadge, James E.

In: Biotherapy, Vol. 4, No. 3, 01.03.1992, p. 215-236.

Research output: Contribution to journalArticle

@article{81caeeb524d646818d83724993f53dcf,
title = "Development of immunotherapeutic strategies for the treatment of malignant neoplasms",
abstract = "Focused preclinical studies have been used to gain insight into the mechanism of therapeutic activity of cytokines, growth factors and biological response modifiers (BRMs). These data can then be used to develop a clinical hypothesis to facilitate the development of these new biological drugs. In this manuscript, we discuss a number of preclinical and clinical studies using interferon-γ, IL-2, and the colony stimulating factors. The importance of the systematic profiling of the biological activity of such biological drugs is emphasized and we discuss the utility of the mechanistic data in their clinical development. The overall preclinical approach identifies the cellular, biochemical or gene regulatory event that is associated with the therapeutic activity of a biologic and this surrogate (be it biological, chemical, or quality of life) is then used to optimize the clinical protocol in a phase lb trial. This, in theory, results in the rapid identification of the optimal dose, schedule and route of administration for subsequent testing in a phase II/III clinical trial.",
keywords = "Biological Response Modifiers (BRMs), colony stimulating factor granulocyte-macrophage (CSF-GM), colony stimulating factor-granulocyte (CSF-G), immunotherapy and immunopharmacology, interferon (IFN), interferon-γ (IFN-γ), interleukin-2 (IL-2), metastasis",
author = "Talmadge, {James E}",
year = "1992",
month = "3",
day = "1",
doi = "10.1007/BF02174208",
language = "English (US)",
volume = "4",
pages = "215--236",
journal = "Biotherapy",
issn = "0921-299X",
publisher = "Springer International Publishing AG",
number = "3",

}

TY - JOUR

T1 - Development of immunotherapeutic strategies for the treatment of malignant neoplasms

AU - Talmadge, James E

PY - 1992/3/1

Y1 - 1992/3/1

N2 - Focused preclinical studies have been used to gain insight into the mechanism of therapeutic activity of cytokines, growth factors and biological response modifiers (BRMs). These data can then be used to develop a clinical hypothesis to facilitate the development of these new biological drugs. In this manuscript, we discuss a number of preclinical and clinical studies using interferon-γ, IL-2, and the colony stimulating factors. The importance of the systematic profiling of the biological activity of such biological drugs is emphasized and we discuss the utility of the mechanistic data in their clinical development. The overall preclinical approach identifies the cellular, biochemical or gene regulatory event that is associated with the therapeutic activity of a biologic and this surrogate (be it biological, chemical, or quality of life) is then used to optimize the clinical protocol in a phase lb trial. This, in theory, results in the rapid identification of the optimal dose, schedule and route of administration for subsequent testing in a phase II/III clinical trial.

AB - Focused preclinical studies have been used to gain insight into the mechanism of therapeutic activity of cytokines, growth factors and biological response modifiers (BRMs). These data can then be used to develop a clinical hypothesis to facilitate the development of these new biological drugs. In this manuscript, we discuss a number of preclinical and clinical studies using interferon-γ, IL-2, and the colony stimulating factors. The importance of the systematic profiling of the biological activity of such biological drugs is emphasized and we discuss the utility of the mechanistic data in their clinical development. The overall preclinical approach identifies the cellular, biochemical or gene regulatory event that is associated with the therapeutic activity of a biologic and this surrogate (be it biological, chemical, or quality of life) is then used to optimize the clinical protocol in a phase lb trial. This, in theory, results in the rapid identification of the optimal dose, schedule and route of administration for subsequent testing in a phase II/III clinical trial.

KW - Biological Response Modifiers (BRMs)

KW - colony stimulating factor granulocyte-macrophage (CSF-GM)

KW - colony stimulating factor-granulocyte (CSF-G)

KW - immunotherapy and immunopharmacology

KW - interferon (IFN)

KW - interferon-γ (IFN-γ)

KW - interleukin-2 (IL-2)

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=0026561856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026561856&partnerID=8YFLogxK

U2 - 10.1007/BF02174208

DO - 10.1007/BF02174208

M3 - Article

C2 - 1599805

AN - SCOPUS:0026561856

VL - 4

SP - 215

EP - 236

JO - Biotherapy

JF - Biotherapy

SN - 0921-299X

IS - 3

ER -